IL3 and chronic myelogenous leukemia, BCR-ABL1 positive: LAMP2B-IL3-engineered EVs were simultaneously loaded with siRNA against oncogenes and the chemotherapeutic agent imatinib, thus targeting CML cells through the IL3 receptor and inhibiting their proliferation107.